Human respiratory syncytial virus epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
(12 intermediate revisions by 5 users not shown)
Line 2: Line 2:
{{Human respiratory syncytial virus}}
{{Human respiratory syncytial virus}}


Please help WikiDoc by adding content here.  It's easy! Click [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
{{CMG}}; {{AE}} {{Bassel}}
==Epidemiology and Demographics==
 
===Incidence===
*In the 2016–2020 season, the incidence of RSV-associated hospitalizations was estimated to be 42-53 per 100,000 individuals.<ref name="urlwww.cdc.gov">{{cite web |url=https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-10-19-20/04-RSV-Adults-Melgar-508.pdf |title=www.cdc.gov |format= |work= |accessdate=2023-01-16}}</ref>
*In the 2022-2023 season, the incidence of RSV-associated hospitalizations was estimated to be 43.4 per 100,000 individuals.<ref name="urlRSV-NET Interactive Dashboard | CDC">{{cite web |url=https://www.cdc.gov/rsv/research/rsv-net/dashboard.html |title=RSV-NET Interactive Dashboard &#124; CDC |format= |work= |accessdate=2023-01-16}}</ref>
 
===Age===
*RSV infection can occur in patients of all ages.
*Infants and young children are most commonly affected by RSV.
*55% of RSV cases occur in individuals under 1 year of age.<ref name="pmid34337092">{{cite journal| author=Staadegaard L, Caini S, Wangchuk S, Thapa B, de Almeida WAF, de Carvalho FC | display-authors=etal| title=The Global Epidemiology of RSV in Community and Hospitalized Care: Findings From 15 Countries. | journal=Open Forum Infect Dis | year= 2021 | volume= 8 | issue= 7 | pages= ofab159 | pmid=34337092 | doi=10.1093/ofid/ofab159 | pmc=8320297 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=34337092 }} </ref>
*8% of RSV cases occur in individuals aged ≥65 years.<ref name="pmid34337092">{{cite journal| author=Staadegaard L, Caini S, Wangchuk S, Thapa B, de Almeida WAF, de Carvalho FC | display-authors=etal| title=The Global Epidemiology of RSV in Community and Hospitalized Care: Findings From 15 Countries. | journal=Open Forum Infect Dis | year= 2021 | volume= 8 | issue= 7 | pages= ofab159 | pmid=34337092 | doi=10.1093/ofid/ofab159 | pmc=8320297 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=34337092 }} </ref>
 
===Mortality Rate===
The overall crude mortality rate due to RVS (cause of death unspecified) in the United States was 7.8 per 100,000 individuals. A breakdown of the mortality rate by age group revealed that the rate was highest among individuals aged 65 years or older, at 46.8 per 100,000. The mortality rate was also elevated among those aged 50-64 years, at 11.8 per 100,000. In contrast, the mortality rate was lower among individuals aged 1-4 years, at 1.1 per 100,000, and even lower among those aged one year or less, at 2.7 per 100,000. <ref name="pmid35226079">{{cite journal| author=Hansen CL, Chaves SS, Demont C, Viboud C| title=Mortality Associated With Influenza and Respiratory Syncytial Virus in the US, 1999-2018. | journal=JAMA Netw Open | year= 2022 | volume= 5 | issue= 2 | pages= e220527 | pmid=35226079 | doi=10.1001/jamanetworkopen.2022.0527 | pmc=8886548 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=35226079 }} </ref>
 
===Seasonal Trends===
RSV circulation in the United States (except Floria and Hawai) and similar climates typically starts in fall and peaks in winter:<ref name="urlRespiratory Syncytial Virus Seasonality — United States, 2014–2017 | MMWR">{{cite web |url=https://www.cdc.gov/mmwr/volumes/67/wr/mm6702a4.htm |title=Respiratory Syncytial Virus Seasonality — United States, 2014–2017 &#124; MMWR |format= |work= |accessdate=2023-01-16}}</ref>
 
* Season onset ranged from mid-September to mid-November.
* Season peak ranged from late December to mid-February.
* Season offset ranged from mid-April to mid-May.
 
Prior to 2020, RSV seasonal patterns in the United States were consistent, but have been disrupted since the onset of the COVID-19 pandemic.<ref name="urlChanges in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic — United States, 2020–2021 | MMWR">{{cite web |url=https://www.cdc.gov/mmwr/volumes/70/wr/mm7029a1.htm |title=Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic — United States, 2020–2021 &#124; MMWR |format= |work= |accessdate=2023-01-16}}</ref>


==References==
==References==
 
{{reflist|2}}
{{Reflist|2}}


[[Category:Viral diseases]]
[[Category:Viral diseases]]
[[Category:Mononegavirales]]
[[Category:Mononegavirales]]
[[Category:Needs content]]


[[Category:Pediatrics]]
[[Category:Pulmonology]]
[[Category:Disease]]
[[Category:Needs overview]]
{{WH}}
{{WH}}
{{WS}}
{{WS}}

Latest revision as of 16:54, 16 January 2023

Human respiratory syncytial virus Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Human Respiratory Syncytial Virus from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Human respiratory syncytial virus epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Human respiratory syncytial virus epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Human respiratory syncytial virus epidemiology and demographics

CDC on Human respiratory syncytial virus epidemiology and demographics

Human respiratory syncytial virus epidemiology and demographics in the news

Blogs on Human respiratory syncytial virus epidemiology and demographics

Directions to Hospitals Treating Human respiratory syncytial virus

Risk calculators and risk factors for Human respiratory syncytial virus epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Bassel Almarie M.D.[2]

Epidemiology and Demographics

Incidence

  • In the 2016–2020 season, the incidence of RSV-associated hospitalizations was estimated to be 42-53 per 100,000 individuals.[1]
  • In the 2022-2023 season, the incidence of RSV-associated hospitalizations was estimated to be 43.4 per 100,000 individuals.[2]

Age

  • RSV infection can occur in patients of all ages.
  • Infants and young children are most commonly affected by RSV.
  • 55% of RSV cases occur in individuals under 1 year of age.[3]
  • 8% of RSV cases occur in individuals aged ≥65 years.[3]

Mortality Rate

The overall crude mortality rate due to RVS (cause of death unspecified) in the United States was 7.8 per 100,000 individuals. A breakdown of the mortality rate by age group revealed that the rate was highest among individuals aged 65 years or older, at 46.8 per 100,000. The mortality rate was also elevated among those aged 50-64 years, at 11.8 per 100,000. In contrast, the mortality rate was lower among individuals aged 1-4 years, at 1.1 per 100,000, and even lower among those aged one year or less, at 2.7 per 100,000. [4]

Seasonal Trends

RSV circulation in the United States (except Floria and Hawai) and similar climates typically starts in fall and peaks in winter:[5]

  • Season onset ranged from mid-September to mid-November.
  • Season peak ranged from late December to mid-February.
  • Season offset ranged from mid-April to mid-May.

Prior to 2020, RSV seasonal patterns in the United States were consistent, but have been disrupted since the onset of the COVID-19 pandemic.[6]

References

  1. ↑ "www.cdc.gov" (PDF). Retrieved 2023-01-16.
  2. ↑ "RSV-NET Interactive Dashboard | CDC". Retrieved 2023-01-16.
  3. ↑ 3.0 3.1 Staadegaard L, Caini S, Wangchuk S, Thapa B, de Almeida WAF, de Carvalho FC; et al. (2021). "The Global Epidemiology of RSV in Community and Hospitalized Care: Findings From 15 Countries". Open Forum Infect Dis. 8 (7): ofab159. doi:10.1093/ofid/ofab159. PMC 8320297 Check |pmc= value (help). PMID 34337092 Check |pmid= value (help).
  4. ↑ Hansen CL, Chaves SS, Demont C, Viboud C (2022). "Mortality Associated With Influenza and Respiratory Syncytial Virus in the US, 1999-2018". JAMA Netw Open. 5 (2): e220527. doi:10.1001/jamanetworkopen.2022.0527. PMC 8886548 Check |pmc= value (help). PMID 35226079 Check |pmid= value (help).
  5. ↑ "Respiratory Syncytial Virus Seasonality — United States, 2014–2017 | MMWR". Retrieved 2023-01-16.
  6. ↑ "Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic — United States, 2020–2021 | MMWR". Retrieved 2023-01-16.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Human_respiratory_syncytial_virus_epidemiology_and_demographics&oldid=1732667"